The US authorities have authorised use of two bivalent COVID-19 booster vaccines from Pfizer/BioNTech and Moderna – targeting the BA.4 and BA.5 subvariants of Omicron – for use in children
A submission to the US Food and Drug Administration (FDA) requesting an Emergency Use Authorization (EUA) of a 10-µg booster dose of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for
The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy t
Pfizer and BioNTech's COVID-19 vaccine targeting Omicron BA.4 and BA.5 has been recommended for authorisation by the EMA's human medicines committee, shortly after the panel gave its blessi
BioNTech has been thrust into the limelight with its mRNA-based vaccines and therapeutics – most notably its Pfizer-partnered COVID-19 shot – but the other side of its business is CAR-T the
